Protalix BioTherapeutics (PLX) Total Liabilities (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Total Liabilities of $35.1 million for Q1 2026, up 22.39% year-over-year from $28.7 million in Q1 2025, and up 2.9% quarter-over-quarter from $34.1 million in Q4 2025.
Protalix BioTherapeutics (PLX) Total Liabilities (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $35.1 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 22.39% year-over-year to $35.1 million; the TTM figure through Mar 2026 stood at $35.1 million (up 22.39% YoY), while the FY2025 annual figure was $34.1 million, up 12.94% from the prior year.
- Total Liabilities for Q1 2026 stood at $35.1 million, up from $34.1 million in the prior quarter.
- The five-year high for Total Liabilities was $75.9 million in Q1 2022, with the low at $28.6 million in Q2 2025.
- The 5-year median for Total Liabilities is $49.4 million (2023), against an average of $49.1 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities climbed 27.41% in 2024, then plunged 54.6% in 2025.
- Protalix BioTherapeutics' Total Liabilities stood at $66.4 million in 2022, then decreased by 23.43% to $50.9 million in 2023, then tumbled by 40.62% to $30.2 million in 2024, then gained by 12.94% to $34.1 million in 2025, then increased by 2.9% to $35.1 million in 2026.
- Business Quant data shows PLX's Total Liabilities at $35.1 million in Q1 2026, $34.1 million in Q4 2025, and $29.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 38.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.93 Mn |
| Mar 31, 2026 | 35.11 Mn |
| Dec 31, 2025 | 34.12 Mn |
| Sep 30, 2025 | 29.36 Mn |
| Jun 30, 2025 | 28.58 Mn |
| Mar 31, 2025 | 28.68 Mn |
| Dec 31, 2024 | 30.21 Mn |
| Sep 30, 2024 | 29.13 Mn |
| Jun 30, 2024 | 62.96 Mn |
| Mar 31, 2024 | 60.04 Mn |
| Dec 31, 2023 | 50.87 Mn |
| Sep 30, 2023 | 49.32 Mn |
| Jun 30, 2023 | 49.42 Mn |
| Mar 31, 2023 | 65.55 Mn |
| Dec 31, 2022 | 66.43 Mn |
| Sep 30, 2022 | 68.22 Mn |
| Jun 30, 2022 | 70.53 Mn |
| Mar 31, 2022 | 75.88 Mn |
| Dec 31, 2021 | 79.70 Mn |
| Sep 30, 2021 | 83.27 Mn |